Workflow
PROCEPT BioRobotics (PRCT)
icon
Search documents
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
Globenewswire· 2025-04-29 20:03
Group 1 - The company, PROCEPT BioRobotics, is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at four investor conferences in May and June 2025, including the Bank of America Health Care Conference and the Jefferies Global Healthcare Conference [1][2] - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] Group 2 - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), impacting approximately 40 million men in the U.S. [3] - The company has developed a significant body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [3] - The company aims to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions [3]
PROCEPT BioRobotics (PRCT) Earnings Call Presentation
2025-04-26 09:15
Key Milestones & Financials - PROCEPT BioRobotics achieved global revenue of $224.5 million in 2024[15] - The company's revenue guidance for 2025 is $323 million[18] - In 2021, PROCEPT BioRobotics had an IPO at $1.2 billion market capitalization[12] HYDROS System & Commercial Update - HYDROS resonates with all BPH hospitals, with a 20% BPH hospital penetration rate[31] - The U.S. install base shows a shift from 1Q23 to 1Q25, with low-volume hospitals decreasing from 73% to 61%, medium-volume increasing from 6% to 8%, and high-volume increasing from 20% to 31%[30] Prostate Cancer & Aquablation Therapy - Approximately 60% of Active Surveillance patients will undergo radical treatment in 10-15 years[100] - In the U.S., 26% of localized prostate cancer diagnoses are high risk, 50% are intermediate risk, and 24% are low risk[79] - Early data from PRCT001 + PRCT002 trials includes 88 prostate cancer patients treated, with 65 having 3-month follow-up and 47 having 6-month follow-up[125] - 70% of prostate cancer patients in PRCT001 + PRCT002 have intermediate-risk disease[127] - 76% of patients in PRCT001 + PRCT002 have cancer in the Peripheral Zone[130]
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
Globenewswire· 2025-04-24 20:03
Core Insights - PROCEPT BioRobotics Corporation is showcasing its leadership in BPH treatment through extensive scientific presentations and workshops at the 2025 AUA Annual Meeting [1][2] - Aquablation therapy is highlighted as a transformative solution for BPH, offering durable symptom relief with minimal side effects [2][15] Company Overview - PROCEPT BioRobotics focuses on advancing urologic care through innovative surgical robotics, specifically the AQUABEAM and HYDROS Robotic Systems [15] - The company aims to revolutionize BPH treatment globally, impacting approximately 40 million men in the United States [15] Clinical Data and Presentations - Clinical presentations at AUA will emphasize long-term outcomes, safety, and durability of Aquablation therapy [2] - A series of thought leader presentations will take place, featuring insights from various experts on the role of Aquablation in modern urology [3][4][5][6][7] Event Activities - PROCEPT's booth will host hands-on demonstrations of the HYDROS Robotic System, allowing urologists to explore the technology and discuss clinical experiences [8] - The AUA Scientific Program will feature multiple podium and poster presentations focused on Aquablation therapy [9][10] Technology and Innovation - Aquablation therapy is described as the first ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, allowing for personalized treatment planning [13] - The technology enables precise and controlled removal of prostate tissue while preserving critical anatomical functions [13]
PROCEPT BioRobotics (PRCT) - 2025 Q1 - Earnings Call Transcript
2025-04-25 04:49
Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $69.2 million, representing a growth of 55% compared to Q1 2024 [7][29] - Gross margin for Q1 2025 was 63.9%, consistent with Q4 2024 and up 750 basis points year-over-year [35] - Net loss for Q1 2025 was $24.7 million, compared to a net loss of $26 million in the same period of the prior year [37] Business Line Data and Key Metrics Changes - US revenue for Q1 2025 was $60.3 million, representing a growth of 50% compared to the prior year [29] - The company sold 43 robotic systems in Q1 2025, with an average selling price of approximately $435,000 [31] - US handpiece revenue for Q1 2025 was $38 million, representing a growth of 61% year-over-year, with 11,235 handpieces sold [33] Market Data and Key Metrics Changes - International revenue in Q1 2025 was $8.9 million, representing growth of 104% compared to the prior year, primarily driven by strong sales in the UK [26][34] - The US installed base of robotic systems reached 547, reflecting a growth of 55% compared to the prior year [8] Company Strategy and Development Direction - The company is focused on expanding the installed base of Hydro systems in greenfield accounts while also seeing interest from existing customers for replacements [39] - The management believes that the current tariff environment will not compromise the path to achieving long-term profitability objectives [44] - The company aims to standardize aquablation therapy across hospital networks, driven by consistent outcomes and operational efficiency [22][112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue growing the installed base and procedural volumes despite macroeconomic challenges [25] - The company anticipates a modest impact on 2025 gross margin due to strong inventory positions and limited exposure to foreign suppliers [11][53] - Management highlighted the positive changes in Medicare coverage that will expand access to aquablation therapy [15][126] Other Important Information - The company is preparing for the AUA conference, where it will present significant clinical data related to aquablation therapy [47][49] - The management is actively evaluating operational strategies to mitigate future tariff exposure [44][102] Q&A Session Summary Question: Can you discuss the CapEx environment and buyer interest in the system? - Management has not seen an impact on capital interest in acquiring Hydro systems, with a strong pipeline and high hospital interest [59][60] Question: How many handpieces sold in Q1 were pushed from Q4? - The impact from deferrals in Q4 was largely offset by the saline issue, resulting in Q1 procedures driven by business strength [66] Question: Can you provide more color on procedure volume growth in March? - March showed a return to normalcy, with guidance for Q2 and Q3 assuming similar utilization rates to Q1 [71][72] Question: What is the current utilization in IDN accounts? - Utilization is driven by surgeons, with IDNs showing interest in educating staff to increase patient volume for aquablation [108][110] Question: How is the company balancing growth in OUS markets? - The company is focusing on the UK as a key market while ensuring disciplined growth strategies [86][87] Question: What are the implications of the recent LCD changes? - The removal of certain limitations will streamline patient pre-workup and expand access to aquablation therapy [126][128]
PROCEPT BioRobotics (PRCT) - 2025 Q1 - Earnings Call Transcript
2025-04-24 18:37
Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $69.2 million, representing a growth of 55% compared to Q1 2024 [7][29] - Gross margin for Q1 2025 was 63.9%, consistent with Q4 2024 and up 750 basis points year-over-year [35] - Net loss for Q1 2025 was $24.7 million, compared to a net loss of $26 million in the same period of the prior year [37] Business Line Data and Key Metrics Changes - US revenue for Q1 2025 was $60.3 million, representing a growth of 50% compared to the prior year [29] - The company sold 43 robotic systems in Q1 2025, with an average selling price of approximately $435,000 [31] - US handpiece revenue for Q1 2025 was $38 million, representing a growth of 61% year-over-year, with 11,235 handpieces sold [33] Market Data and Key Metrics Changes - International revenue in Q1 2025 was $8.9 million, representing growth of 104% compared to the prior year, driven primarily by strong sales in the UK [26][34] - The US installed base of robotic systems reached 547, reflecting a growth of 55% compared to the prior year [8] Company Strategy and Development Direction - The company is focused on expanding the installed base of Hydro systems in greenfield accounts while also seeing interest from existing customers for replacements [39] - The management believes that the current tariff environment will not compromise the path to achieving long-term profitability objectives [44] - The company aims to standardize aquablation therapy across hospital networks, driven by consistent outcomes and operational efficiency [22][112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue growing the installed base and procedural volumes despite macroeconomic challenges [25][39] - The company anticipates a modest impact on 2025 gross margin due to strong inventory positions and limited exposure to foreign suppliers [11][53] - Management highlighted the positive changes in Medicare coverage that will streamline access to aquablation therapy for a broader patient population [15][126] Other Important Information - The company is preparing for the AUA conference, where it will present data from trials that could influence future treatment guidelines for prostate cancer [49][50] - The company has received IDE approval from the FDA to enroll a randomized trial comparing surgical therapy against radical prostatectomy for prostate cancer [50] Q&A Session Summary Question: Can you discuss the CapEx environment and buyer interest in the system? - Management noted that there has been no impact on capital interest in acquiring Hydro systems, with a strong pipeline and daily conversations indicating continued excitement [59][60] Question: What was the procedure volume growth in March? - Management reported a return to normalcy in March, with guidance for Q2 and Q3 assuming similar utilization rates to Q1 [71][72] Question: How do you view the utilization in IDNs? - Management indicated that IDNs are increasingly interested in standardizing procedures and improving utilization through education and support [106][112] Question: What are the implications of the LCD changes? - Management stated that the removal of certain limitations will streamline patient pre-workup and expand access to aquablation therapy [126][128] Question: How is the company balancing growth in international markets? - Management emphasized a disciplined approach to entering new markets, focusing on the UK and Japan while ensuring strong support in existing markets [86][87]
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-04-24 13:20
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago. These figures are adju ...
PROCEPT BioRobotics (PRCT) - 2025 Q1 - Quarterly Results
2025-04-24 11:06
Revenue Growth - Total revenue for Q1 2025 was $69.2 million, a 55% increase compared to Q1 2024[4] - U.S. revenue reached $60.3 million, reflecting a growth of 50% year-over-year[4] - U.S. handpiece and consumable revenue was $38.0 million, up 61% from the prior year[4] - International revenue was $8.9 million, representing a 104% increase compared to the previous year[4] - Total revenue for PROCEPT BioRobotics Corporation in Q1 2025 reached $69,162,000, a significant increase from $44,539,000 in Q1 2024, representing a growth of 55.4%[26] - U.S. revenue totaled $60,294,000 in Q1 2025, up from $40,201,000 in Q1 2024, marking a year-over-year increase of 50.1%[26] - Revenue from handpieces and other consumables in the U.S. rose to $38,011,000, compared to $23,618,000 in the previous year, reflecting a growth of 60.7%[26] - Total revenue outside of the U.S. was $8,868,000 in Q1 2025, more than doubling from $4,338,000 in Q1 2024, indicating a growth of 104.1%[26] - Handpieces and other consumables revenue outside the U.S. increased to $4,477,000, compared to $2,343,000 in the prior year, showing a growth of 90.1%[26] - Service revenue in the U.S. grew to $3,596,000, up from $2,347,000, representing a year-over-year increase of 53.2%[26] - Service revenue outside the U.S. also saw growth, reaching $538,000 compared to $255,000, which is a 111.4% increase[26] Financial Performance - Gross margin for Q1 2025 improved to 64%, compared to 56% in Q1 2024[5] - Operating expenses for Q1 2025 totaled $71.6 million, an increase from $52.7 million in the prior year[6] - Net loss for Q1 2025 was $24.7 million, an improvement from a loss of $26.0 million in Q1 2024[7] - The company increased its full-year 2025 revenue guidance to $323 million, a 44% growth compared to the previous year[10] - The projected full-year 2025 Adjusted EBITDA loss is expected to be $35.0 million, unchanged from prior guidance[12] Market Presence and Innovation - As of March 31, 2025, the company had an installed base of 547 robotic systems in the U.S.[4] - The company continues to focus on expanding its market presence and enhancing its product offerings to drive future growth[26] - PROCEPT BioRobotics Corporation is committed to ongoing research and development to innovate new products and technologies in the medical robotics field[26]
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Newsfilter· 2025-04-24 11:00
Core Insights - PROCEPT BioRobotics Corporation reported a strong performance in Q1 2025, achieving total revenue growth of 55% year-over-year, driven by robust procedural momentum and strategic placements of its Hydros™ system [3][4]. Financial Performance - Total revenue for Q1 2025 was $69.2 million, a 55% increase compared to $44.5 million in Q1 2024 [4][9]. - U.S. revenue reached $60.3 million, reflecting a 50% growth from the previous year, primarily due to system sales and increased handpiece revenue [4][9]. - U.S. handpiece and consumable revenue was $38.0 million, up 61% year-over-year, while system revenue was $18.7 million, a 31% increase [4][9]. - International revenue was $8.9 million, marking a significant 104% increase compared to the prior year [4][9]. Profitability Metrics - Gross margin for Q1 2025 improved to 64%, up from 56% in the prior year, attributed to operational efficiencies and higher average selling prices [5]. - Operating expenses increased to $71.6 million from $52.7 million in the previous year, driven by expansion of the commercial organization and increased R&D expenses [6]. - The net loss for Q1 2025 was $24.7 million, slightly improved from a loss of $26.0 million in Q1 2024 [7][19]. - Adjusted EBITDA loss was $15.8 million, compared to a loss of $20.4 million in the prior year [7][19]. Future Guidance - The company raised its full-year 2025 revenue guidance to $323 million, representing a 44% increase over the previous year [10][11]. - Projected gross margin for the full year is approximately 64.5%, with potential headwinds from global tariff rates estimated to impact margins by about 150 basis points [10][11]. - Total operating expenses for 2025 are projected to be around $300 million, with an expected Adjusted EBITDA loss of $35 million [11]. Market Position and Strategy - The U.S. launch of the Hydros™ system is gaining traction, particularly among large Integrated Delivery Networks, with 45% of U.S. system placements coming from corporate multi-unit orders [3][4]. - The company aims to revolutionize BPH treatment through its robotic solutions, with a focus on delivering effective outcomes for patients [12].
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
Globenewswire· 2025-04-10 20:03
Company Overview - PROCEPT BioRobotics Corporation aims to revolutionize BPH treatment globally by providing advanced robotic solutions that enhance patient outcomes and deliver value [3] - The company manufactures the AQUABEAM® and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology for Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH, regardless of prostate size, shape, or surgeon experience [3] - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for the company's solutions [3] - PROCEPT BioRobotics has established a robust clinical foundation with over 150 peer-reviewed publications supporting the efficacy and advantages of Aquablation therapy [3] Upcoming Investor Event - The company will host an in-person investor event on April 25, 2025, at the Aria Resort in Las Vegas during the American Urological Association Annual Meeting [1] - The event will feature presentations from the management team and clinical perspectives from various physicians [2] - A live webcast of the event will be available, along with an archived recording accessible for at least 90 days post-event [2]
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Globenewswire· 2025-03-24 12:00
Core Insights - Aquablation therapy shows comparable symptom relief to laser enucleation while significantly preserving ejaculatory function and continence in patients with large prostates [1][2][4] Group 1: Study Overview - The WATER III trial is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation for prostate sizes between 80-180 mL, involving 186 men treated from December 2020 to September 2024 [2] - The study reported three-month primary safety and efficacy endpoints, with plans to follow patients for five years [2] Group 2: Clinical Outcomes - Aquablation therapy resulted in a 14.8% rate of ejaculatory dysfunction compared to 77.1% for laser enucleation, and a 0% rate of stress incontinence compared to 9.1% for laser enucleation [2] - The procedural transfusion rate for Aquablation therapy was 0%, indicating a strong safety profile in managing bleeding risk [3] Group 3: Expert Commentary - The CEO of PROCEPT BioRobotics emphasized that the results of the WATER III trial reinforce the company's commitment to establishing Aquablation therapy as the standard of care for BPH, highlighting its effectiveness in preserving quality of life factors [4] - Dr. Naeem Bhojani noted that the consistent efficacy and lower rates of complications represent a significant advancement for patients seeking BPH treatment [4] Group 4: Technology and Innovation - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, allowing for personalized treatment planning based on real-time imaging [5] - The technology enables precise and controlled removal of prostate tissue while preserving critical anatomical structures [5] Group 5: Company Background - PROCEPT BioRobotics is focused on advancing patient care through innovative urology solutions, manufacturing the AQUABEAM and HYDROS Robotic Systems [6] - The company has developed a substantial body of clinical evidence, including over 150 peer-reviewed publications, supporting the benefits of Aquablation therapy [7]